<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:vogx="http://www.vogenx.com/20260630"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vogx-20260630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <instant>2026-09-17</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vogx:SeriesAConvertibleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vogx:SeriesAConvertibleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vogx:SeriesAConvertibleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vogx:SeriesAConvertibleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vogx:SeriesAConvertibleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vogx:SeriesAConvertibleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-01</startDate>
            <endDate>2026-08-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-08-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-01</startDate>
            <endDate>2026-08-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-08-13</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">vogx:ConvertiblePromissoryNotesPayableRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">vogx:ConvertiblePromissoryNotesPayableRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">vogx:ConvertiblePromissoryNotesPayableRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">vogx:ConvertiblePromissoryNotesPayableRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">vogx:ConvertiblePromissoryNotesPayableRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">vogx:ProbabilityWeightedAverageReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vogx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <instant>2025-12-08</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <startDate>2025-12-08</startDate>
            <endDate>2025-12-08</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vogx:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vogx:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vogx:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vogx:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vogx:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vogx:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vogx:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vogx:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vogx:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vogx:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vogx:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vogx:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vogx:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vogx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vogx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vogx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vogx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001903784</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>vogx:segment</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-10895">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0" id="ixv-10896">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-10897">2026-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-10898">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-10899">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-10900">001-43441</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-110">Vogenx, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-122">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-126">86-3697324</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-147">PO Box 19469</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-10901">Raleigh</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-10902">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-10903">27619</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-10904">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-10905">659-5677</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-184">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-188">VOGX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-10906">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-10907">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-10908">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-223">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-10909">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-10910">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0" id="ixv-10911">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c0" id="ixv-10912">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-10913"
      unitRef="shares">14855087</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" id="ixv-10914" unitRef="usd">193017</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" id="ixv-10915" unitRef="usd">601010</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DeferredOfferingCosts contextRef="c2" decimals="0" id="ixv-10916" unitRef="usd">1204631</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts contextRef="c3" decimals="0" id="ixv-10917" unitRef="usd">63363</us-gaap:DeferredOfferingCosts>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-10918" unitRef="usd">11380</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-10919" unitRef="usd">16797</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" id="ixv-10920" unitRef="usd">1409028</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" id="ixv-10921" unitRef="usd">681170</us-gaap:AssetsCurrent>
    <us-gaap:Assets contextRef="c2" decimals="0" id="ixv-10922" unitRef="usd">1409028</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-10923" unitRef="usd">681170</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="0" id="ixv-10924" unitRef="usd">1223671</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" id="ixv-10925" unitRef="usd">62964</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-10926" unitRef="usd">1095543</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-10927" unitRef="usd">709818</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c2" decimals="0" id="ixv-10928" unitRef="usd">1415</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c3" decimals="0" id="ixv-10929" unitRef="usd">11323</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c2" decimals="0" id="ixv-10930" unitRef="usd">867700</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c3" decimals="0" id="ixv-10931" unitRef="usd">816300</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-10932" unitRef="usd">3188329</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-10933" unitRef="usd">1600405</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="0" id="ixv-10934" unitRef="usd">3188329</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="0" id="ixv-10935" unitRef="usd">1600405</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c2" decimals="0" id="ixv-10936" unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies contextRef="c3" decimals="0" id="ixv-10937" unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="4"
      id="ixv-10938"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="4"
      id="ixv-10939"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-10940"
      unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c3"
      decimals="INF"
      id="ixv-10941"
      unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-10942"
      unitRef="shares">5661422</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ixv-10943"
      unitRef="shares">5661422</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-10944"
      unitRef="shares">5661422</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-10945"
      unitRef="shares">5661422</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c2" decimals="0" id="ixv-10946" unitRef="usd">566</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c3" decimals="0" id="ixv-10947" unitRef="usd">566</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="4"
      id="ixv-10948"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="4"
      id="ixv-10949"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-10950"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="INF"
      id="ixv-10951"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-10952"
      unitRef="shares">5263158</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ixv-10953"
      unitRef="shares">5263158</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-10954"
      unitRef="shares">5263158</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-10955"
      unitRef="shares">5263158</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" id="ixv-10956" unitRef="usd">526</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" id="ixv-10957" unitRef="usd">526</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" id="ixv-10958" unitRef="usd">9921159</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" id="ixv-10959" unitRef="usd">9921343</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" id="ixv-10960" unitRef="usd">-11701552</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" id="ixv-10961" unitRef="usd">-10841670</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-10962" unitRef="usd">-1779301</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-10963" unitRef="usd">-919235</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" id="ixv-10964" unitRef="usd">1409028</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" id="ixv-10965" unitRef="usd">681170</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" id="ixv-10966" unitRef="usd">156786</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" id="ixv-10967" unitRef="usd">136392</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-10968" unitRef="usd">394695</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="0" id="ixv-10969" unitRef="usd">305703</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="0" id="ixv-10970" unitRef="usd">198598</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" id="ixv-10971" unitRef="usd">174268</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-10972" unitRef="usd">423841</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="0" id="ixv-10973" unitRef="usd">377155</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="0" id="ixv-10974" unitRef="usd">355384</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" id="ixv-10975" unitRef="usd">310660</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-10976" unitRef="usd">818536</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="0" id="ixv-10977" unitRef="usd">682858</us-gaap:OperatingExpenses>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c4" decimals="0" id="ixv-10978" unitRef="usd">-2831</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c5" decimals="0" id="ixv-10979" unitRef="usd">-14154</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c0" decimals="0" id="ixv-10980" unitRef="usd">-9908</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c6" decimals="0" id="ixv-10981" unitRef="usd">-26892</us-gaap:FairValueAdjustmentOfWarrants>
    <vogx:ChangeInFairValueOfConvertiblePromissoryNotesPayableRelatedParty contextRef="c4" decimals="0" id="ixv-10982" unitRef="usd">31900</vogx:ChangeInFairValueOfConvertiblePromissoryNotesPayableRelatedParty>
    <vogx:ChangeInFairValueOfConvertiblePromissoryNotesPayableRelatedParty contextRef="c5" decimals="0" id="ixv-10983" unitRef="usd">0</vogx:ChangeInFairValueOfConvertiblePromissoryNotesPayableRelatedParty>
    <vogx:ChangeInFairValueOfConvertiblePromissoryNotesPayableRelatedParty contextRef="c0" decimals="0" id="ixv-10984" unitRef="usd">51400</vogx:ChangeInFairValueOfConvertiblePromissoryNotesPayableRelatedParty>
    <vogx:ChangeInFairValueOfConvertiblePromissoryNotesPayableRelatedParty contextRef="c6" decimals="0" id="ixv-10985" unitRef="usd">0</vogx:ChangeInFairValueOfConvertiblePromissoryNotesPayableRelatedParty>
    <us-gaap:InvestmentIncomeInterest contextRef="c4" decimals="0" id="ixv-10986" unitRef="usd">23</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c5" decimals="0" id="ixv-10987" unitRef="usd">1709</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="0" id="ixv-10988" unitRef="usd">146</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c6" decimals="0" id="ixv-10989" unitRef="usd">4550</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="0" id="ixv-10990" unitRef="usd">-29046</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="0" id="ixv-10991" unitRef="usd">15863</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-10992" unitRef="usd">-41346</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c6" decimals="0" id="ixv-10993" unitRef="usd">31442</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" id="ixv-10994" unitRef="usd">-384430</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-10995" unitRef="usd">-294797</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-10996" unitRef="usd">-859882</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-10997" unitRef="usd">-651416</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="ixv-10998"
      unitRef="usdPershares">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c4"
      decimals="2"
      id="ixv-10999"
      unitRef="usdPershares">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="ixv-11000"
      unitRef="usdPershares">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c5"
      decimals="2"
      id="ixv-11001"
      unitRef="usdPershares">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-11002"
      unitRef="usdPershares">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-11003"
      unitRef="usdPershares">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-11004"
      unitRef="usdPershares">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-11005"
      unitRef="usdPershares">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-11006"
      unitRef="shares">5451873</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c4"
      decimals="INF"
      id="ixv-11007"
      unitRef="shares">5451873</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-11008"
      unitRef="shares">5451873</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="INF"
      id="ixv-11009"
      unitRef="shares">5451873</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-11010"
      unitRef="shares">5451873</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-11011"
      unitRef="shares">5451873</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="INF"
      id="ixv-11012"
      unitRef="shares">5451873</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="INF"
      id="ixv-11013"
      unitRef="shares">5451873</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="ixv-11014"
      unitRef="shares">5661422</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" id="ixv-11015" unitRef="usd">566</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-11016"
      unitRef="shares">5263158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" id="ixv-11017" unitRef="usd">526</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" id="ixv-11018" unitRef="usd">9904559</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="0" id="ixv-11019" unitRef="usd">-9396067</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="0" id="ixv-11020" unitRef="usd">509584</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c12" decimals="0" id="ixv-11021" unitRef="usd">2621</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c13" decimals="0" id="ixv-11022" unitRef="usd">2621</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="0" id="ixv-11023" unitRef="usd">-356619</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="0" id="ixv-11024" unitRef="usd">-356619</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c15"
      decimals="INF"
      id="ixv-11025"
      unitRef="shares">5661422</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="0" id="ixv-11026" unitRef="usd">566</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c16"
      decimals="INF"
      id="ixv-11027"
      unitRef="shares">5263158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="0" id="ixv-11028" unitRef="usd">526</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" id="ixv-11029" unitRef="usd">9907180</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" id="ixv-11030" unitRef="usd">-9752686</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" id="ixv-11031" unitRef="usd">155586</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c20" decimals="0" id="ixv-11032" unitRef="usd">2621</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c5" decimals="0" id="ixv-11033" unitRef="usd">2621</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c21" decimals="0" id="ixv-11034" unitRef="usd">-294797</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-11035" unitRef="usd">-294797</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c22"
      decimals="INF"
      id="ixv-11036"
      unitRef="shares">5661422</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="0" id="ixv-11037" unitRef="usd">566</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c23"
      decimals="INF"
      id="ixv-11038"
      unitRef="shares">5263158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="0" id="ixv-11039" unitRef="usd">526</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="0" id="ixv-11040" unitRef="usd">9909801</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="0" id="ixv-11041" unitRef="usd">-10047483</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="0" id="ixv-11042" unitRef="usd">-136590</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c27"
      decimals="INF"
      id="ixv-11043"
      unitRef="shares">5661422</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="0" id="ixv-11044" unitRef="usd">566</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c28"
      decimals="INF"
      id="ixv-11045"
      unitRef="shares">5263158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="0" id="ixv-11046" unitRef="usd">526</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="0" id="ixv-11047" unitRef="usd">9921343</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="0" id="ixv-11048" unitRef="usd">-10841670</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-11049" unitRef="usd">-919235</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c31" decimals="0" id="ixv-11050" unitRef="usd">-4852</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c32" decimals="0" id="ixv-11051" unitRef="usd">-4852</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c33" decimals="0" id="ixv-11052" unitRef="usd">-475452</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c32" decimals="0" id="ixv-11053" unitRef="usd">-475452</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c34"
      decimals="INF"
      id="ixv-11054"
      unitRef="shares">5661422</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="0" id="ixv-11055" unitRef="usd">566</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c35"
      decimals="INF"
      id="ixv-11056"
      unitRef="shares">5263158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="0" id="ixv-11057" unitRef="usd">526</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c36" decimals="0" id="ixv-11058" unitRef="usd">9916491</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c37" decimals="0" id="ixv-11059" unitRef="usd">-11317122</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c38" decimals="0" id="ixv-11060" unitRef="usd">-1399539</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c39" decimals="0" id="ixv-11061" unitRef="usd">4668</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c4" decimals="0" id="ixv-11062" unitRef="usd">4668</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c40" decimals="0" id="ixv-11063" unitRef="usd">-384430</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" id="ixv-11064" unitRef="usd">-384430</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c41"
      decimals="INF"
      id="ixv-11065"
      unitRef="shares">5661422</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="0" id="ixv-11066" unitRef="usd">566</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c42"
      decimals="INF"
      id="ixv-11067"
      unitRef="shares">5263158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="0" id="ixv-11068" unitRef="usd">526</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="0" id="ixv-11069" unitRef="usd">9921159</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c44" decimals="0" id="ixv-11070" unitRef="usd">-11701552</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-11071" unitRef="usd">-1779301</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-11072" unitRef="usd">-859882</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-11073" unitRef="usd">-651416</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" id="ixv-11074" unitRef="usd">-184</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="0" id="ixv-11075" unitRef="usd">5242</us-gaap:ShareBasedCompensation>
    <vogx:ChangeInFairValueOfConvertiblePromissoryNotesPayableRelatedParty contextRef="c0" decimals="0" id="ixv-11076" unitRef="usd">51400</vogx:ChangeInFairValueOfConvertiblePromissoryNotesPayableRelatedParty>
    <vogx:ChangeInFairValueOfConvertiblePromissoryNotesPayableRelatedParty contextRef="c6" decimals="0" id="ixv-11077" unitRef="usd">0</vogx:ChangeInFairValueOfConvertiblePromissoryNotesPayableRelatedParty>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c0" decimals="0" id="ixv-11078" unitRef="usd">-9908</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c6" decimals="0" id="ixv-11079" unitRef="usd">-26892</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" id="ixv-11080" unitRef="usd">-5417</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c6" decimals="0" id="ixv-11081" unitRef="usd">9697</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="0" id="ixv-11082" unitRef="usd">104313</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c6" decimals="0" id="ixv-11083" unitRef="usd">-39259</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c0" decimals="0" id="ixv-11084" unitRef="usd">385725</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c6" decimals="0" id="ixv-11085" unitRef="usd">149375</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-11086" unitRef="usd">-323119</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="0" id="ixv-11087" unitRef="usd">-572647</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c0" decimals="0" id="ixv-11088" unitRef="usd">84874</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c6" decimals="0" id="ixv-11089" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-11090" unitRef="usd">-84874</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c6" decimals="0" id="ixv-11091" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-11092" unitRef="usd">-407993</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c6" decimals="0" id="ixv-11093" unitRef="usd">-572647</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-11094" unitRef="usd">601010</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c11" decimals="0" id="ixv-11095" unitRef="usd">962923</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-11096" unitRef="usd">193017</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c26" decimals="0" id="ixv-11097" unitRef="usd">390276</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <vogx:DeferredOfferingCost contextRef="c0" decimals="0" id="ixv-11098" unitRef="usd">-1056394</vogx:DeferredOfferingCost>
    <vogx:DeferredOfferingCost contextRef="c6" decimals="0" id="ixv-11099" unitRef="usd">0</vogx:DeferredOfferingCost>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-2922">&lt;table cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0%"&gt;&lt;/td&gt;
    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Organization and Nature of Business&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Vogenx, Inc. (the &#x201c;Company&#x201d;), was incorporated in the State
of Delaware on February 5, 2021. The Company is a clinical-stage life science and drug development company focused on the discovery and
development of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases associated with dysfunctions in
human metabolism and high unmet medical needs. The Company&#x2019;s lead product candidate, mizagliflozin, is an orally administered, minimally
absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (&#x201c;PBH&#x201d;), gastroparesis
and GIP-induced Cushing&#x2019;s Syndrome.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-2935">&lt;table cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0%"&gt;&lt;/td&gt;
    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.1pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Basis of presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The accompanying unaudited condensed financial statements as of June
30, 2026 and for the three and six months ended June 30, 2026 and 2025 have been prepared in accordance with U.S. generally accepted accounting
principles (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim
financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual
financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In the opinion of management, the accompanying unaudited condensed
financial statements reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the
Company&#x2019;s financial position, results of operations, and cash flows as of and for the interim periods presented. The results of operations
for the three and six months ended June 30, 2026 are not necessarily indicative of the results that may be expected for the full fiscal
year or any subsequent interim period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The condensed balance sheet as of December 31, 2025 has been derived
from the audited financial statements as of that date but does not include all disclosures required by U.S. GAAP for complete annual financial
statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;These unaudited condensed financial statements should be read in conjunction
with the Company&#x2019;s audited financial statements and related notes as of and for the year ended December 31, 2025 included in the
Company&#x2019;s final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company&#x2019;s significant accounting policies are described in the
audited financial statements and related notes included in the Company&#x2019;s final prospectus filed pursuant to Rule 424(b). There have
been no material changes to the Company&#x2019;s significant accounting policies during the six months ended June 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;The Company has incurred recurring losses
from operations and had an accumulated deficit of approximately $11.7 million as of June 30, 2026. Since inception, the Company has financed
its operations primarily through the issuance of equity securities and convertible notes. As of June 30, 2026, the Company had cash and
cash equivalents of $193 thousand.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During August 2026, the Company completed its
initial public offering (the &#x201c;IPO&#x201d;). Including proceeds from the exercise of the underwriter&#x2019;s over-allotment option,
the Company received aggregate net proceeds of approximately $84.9 million from the IPO after deducting underwriting discounts and commissions
and offering expenses payable by the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;Management considered the successful completion
of the IPO and the exercise of the overallotment option in its evaluation of the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;Based on the Company&#x2019;s current operating
plan and available cash resources, including the net proceeds received from the IPO and related overallotment option exercise, management
believes the Company&#x2019;s cash and cash equivalents will be sufficient to fund operations and meet its obligations for at least 12
months from the date these financial statements are issued. Accordingly, management has concluded that substantial doubt regarding the
Company&#x2019;s ability to continue as a going concern does not exist.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;The accompanying financial statements have
been prepared on a going concern basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Reverse stock split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;On July 21, 2026 the Company&#x2019;s board
of directors approved a one-for-three reverse stock split, which was effected on July 28, 2026, of the Company&#x2019;s issued and outstanding
shares of common stock. Accordingly, all issued and outstanding share and per share amounts of common stock and stock option awards for
all periods presented in the accompanying financial statements and notes thereto have been adjusted retroactively, where applicable, to
reflect this reverse stock split. The par value of the common stock and preferred stock and the number of authorized shares were not changed
as a result of the reverse stock split.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Initial public offering &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;In August 2026, the Company completed the
IPO, pursuant to which the Company issued and sold 7,187,500 shares of its common stock at a public offering price of $13.00 per share,
including 937,500 additional shares of its common stock pursuant to the exercise in full by the underwriter of its option to purchase
shares of common stock from the Company at the IPO price. As a result, the Company received net proceeds from the IPO of approximately
$84.9 million, after deducting underwriting discounts, commissions and offering expenses payable by the Company. Immediately prior to
the closing of the IPO, the Company&#x2019;s outstanding convertible preferred stock and convertible notes automatically converted into
1,951,246 shares of common stock and the Company&#x2019;s outstanding warrants were automatically cashlessly exercised for 453,183 shares
of common stock.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;Following the closing of the IPO, no shares
of the Company&#x2019;s convertible preferred stock were authorized or outstanding. In connection with the completion of the IPO, on August
13, 2026, the Company&#x2019;s amended and restated certificate of incorporation, as amended, was amended and restated to (i) authorize
500 million shares of common stock, par value $0.0001 per share and (ii) authorize 10 million shares of undesignated preferred stock,
par value $0.0001 per share, that may be issued from time to time by the Company&#x2019;s board of directors from time to time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;The Company&#x2019;s unaudited condensed financial
statements as of and for the period ended June 30, 2026, including share and per share amounts, do not give effect to the IPO and related
actions as the IPO closed subsequent to June 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Certain amounts reported previously have been reclassified to conform
to the current period presentation with no effect on total stockholders&#x2019; deficit or net loss as previously reported.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Segment information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company operates as a &lt;span style="-sec-ix-hidden: hidden-fact-0"&gt;single&lt;/span&gt; reportable segment engaged in the
discovery and development of treatments for serious metabolic and gastrointestinal diseases. The Company has not generated revenues since
inception. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is its Chief Executive Officer. The CODM reviews the
Company&#x2019;s performance on an aggregate basis; thus the segment&#x2019;s loss is the Company&#x2019;s net loss, as reported on accompanying
statements of operations, and the segment&#x2019;s assets are the Company&#x2019;s total assets, as reported on the accompanying balance
sheets. Significant expenses provided to the CODM include research and development and general and administrative expenses, as reported
on the accompanying statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The CODM uses the information primarily to evaluate the Company&#x2019;s
performance and allocate resources. The CODM&#x2019;s evaluation includes reviewing key financial metrics such as budget versus actual
expenditures and assessing overall cash flow and liquidity to ensure the continuity of operations. This approach allows the CODM to monitor
the Company&#x2019;s performance and make strategic adjustments as needed to support its operational and financial goals.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company&#x2019;s operations and all long-lived assets are located
in the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table presents the measure of segment loss and the significant
expense categories regularly provided to the CODM for the three and six months ended June 30, 2026 and June 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="font-size: 9pt; vertical-align: bottom"&gt;
    &lt;td style="font-size: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three&lt;br/&gt; Months Ended &lt;br/&gt; June 30,&lt;br/&gt; 2026&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three&lt;br/&gt; Months Ended &lt;br/&gt; June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six &lt;br/&gt; Months Ended &lt;br/&gt; June 30,&lt;br/&gt; 2026&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six&lt;br/&gt; Months Ended &lt;br/&gt; June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Significant segment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 9pt"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;156,786&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;136,392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;394,695&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;305,703&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,598&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;174,268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;423,841&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;377,155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Other segment expense (income)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;29,046&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(15,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;41,346&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(31,442&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Segment net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(384,430&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(294,797&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(859,882&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(651,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Deferred offering costs &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;The Company capitalizes as deferred offering
costs all direct and incremental legal, accounting, underwriting and other third-party fees incurred in connection with the IPO. Upon
the consummation of the IPO, such costs are offset against the gross proceeds received from the IPO. As of June 30, 2026 and December
31, 2025, the Company had deferred offering costs of $1,204,631 and $63,363, respectively, of which $1,056,394 was included in accounts
payable as of June 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Fair value measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;ASC Topic 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, establishes a fair value
hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Level 1&lt;/i&gt; &#x2013; This level consists of quoted prices (unadjusted)
for identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Level 2&lt;/i&gt; - This level consists of inputs that include quoted
prices for similar assets and liabilities in active markets and inputs that are observable for the asset or liability, either directly
or indirectly, for substantially the full term of the financial instrument. Fair values for these instruments are estimated using pricing
models, quoted prices of securities with similar characteristics, or discounted cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Level 3&lt;/i&gt; - This level consists of inputs that are unobservable
inputs for the assets or liability, which are typically based on an entity&#x2019;s own assumptions, as there is little, if any, related
market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair
value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level
input that is significant to the fair value measurement in its entirety.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The carrying amounts of the Company&#x2019;s financial instruments,
which include cash and cash equivalents, prepaids and other current assets, accounts payable, deferred offering costs and accrued expenses
approximate their fair values at June 30, 2026 and December 31, 2025 due to their short-term nature for these Level 1 instruments and
management&#x2019;s conclusion that their carrying amounts approximate the amount for which the assets could be sold or the liabilities
could be settled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of June 30, 2026, and December 31, 2025, the Company&#x2019;s liabilities
measured at fair value on a recurring basis included the warrant liability and convertible promissory notes payable, related party which
were measured using Level 3 inputs. There were no transfers between fair value hierarchy levels during the three and six months ended
June 30, 2026, and the year ended December 31, 2025.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table summarizes the change in fair value, as determined
by the Level 3 inputs, for the warrant liability, and convertible promissory notes payable, related party using unobservable Level 3 inputs
as of June 30, 2026 and December 31, 2025:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Convertible&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Warrant&lt;br/&gt;
    Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Promissory
    Notes&lt;br/&gt;
    Payable,&lt;br/&gt;
    Related&lt;br/&gt;
    Party&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;65,107&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Fair value balance as of December 8, 2025, issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;810,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(53,784&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Balance as of December 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;816,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9,908&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;51,400&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of June 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,415&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;867,700&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table presents quantitative information about the
inputs and valuation methodologies used for the Company&#x2019;s fair value measurements classified as Level 3 as of June 30, 2026 and
December 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;As
    of June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Valuation
    Methodology&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Significant
    Input&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    (range, if applicable)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 35%; text-align: left"&gt;Convertible promissory notes payable, related
    party&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Probability Weighted Average Return Method (PWERM)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 21%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit spread
    &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;9.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.9-4.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Probability &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0-100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25-0.69 years&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Black-Scholes Option Pricing Model&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.01&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annualized volatility&#160;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Expected term&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.5 years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;As
    of December&#160;31,&#160;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Valuation
    Methodology&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Significant
    Input&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Weighted&lt;br/&gt;

    Average &lt;br/&gt;
(range, if applicable)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 35%; text-align: left"&gt;Convertible promissory notes payable, related
    party&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Probability Weighted Average Return Method (PWERM)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 21%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit spread
    &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;8.9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.5-3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Probability &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0-100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.5 &#x2013; 1.18 years&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Black-Scholes Option Pricing Model&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.73&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annualized volatility&#160;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Expected term&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.97 years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: justify"&gt;Represents significant unobservable input&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Recently issued accounting pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;From time to time, new accounting pronouncements
are issued by the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) or other standard-setting bodies and adopted by the Company
as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that
are not yet effective will not have a material impact on the accompanying financial statements and disclosures.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;In December 2025, the FASB issued ASU 2025-11
- Interim Reporting (Topic 270): Narrow-Scope Improvements (&#x201c;ASU 2025-11&#x201d;). ASU 2025-11 is intended to clarify and improve
certain aspects of interim financial reporting, including the requirements for interim disclosures and the application of recognition
and measurement guidance in interim periods. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning
after December 15, 2027. The Company is currently evaluating the potential impact of the guidance and potential additional disclosures
required.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;On November 2024, the FASB issued ASU 2024-03
- Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement
Expenses. This new standard requires more detailed disclosures about the types of expenses in commonly presented expense captions such
as cost of sales, selling, general and administrative expenses and research and development expenses. This includes separate footnote
disclosure for expenses such as purchases of inventory, employee compensation, depreciation, and intangible asset amortization. Public
business entities are required to apply the guidance prospectively and may apply it retrospectively. The ASU&#x2019;s amendments are effective
for public business entities for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December
15, 2027. The Company is currently evaluating the effect of adopting this ASU.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-2944">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Basis of presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The accompanying unaudited condensed financial statements as of June
30, 2026 and for the three and six months ended June 30, 2026 and 2025 have been prepared in accordance with U.S. generally accepted accounting
principles (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim
financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual
financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In the opinion of management, the accompanying unaudited condensed
financial statements reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the
Company&#x2019;s financial position, results of operations, and cash flows as of and for the interim periods presented. The results of operations
for the three and six months ended June 30, 2026 are not necessarily indicative of the results that may be expected for the full fiscal
year or any subsequent interim period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The condensed balance sheet as of December 31, 2025 has been derived
from the audited financial statements as of that date but does not include all disclosures required by U.S. GAAP for complete annual financial
statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;These unaudited condensed financial statements should be read in conjunction
with the Company&#x2019;s audited financial statements and related notes as of and for the year ended December 31, 2025 included in the
Company&#x2019;s final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company&#x2019;s significant accounting policies are described in the
audited financial statements and related notes included in the Company&#x2019;s final prospectus filed pursuant to Rule 424(b). There have
been no material changes to the Company&#x2019;s significant accounting policies during the six months ended June 30, 2026.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <vogx:LiquidityPolicyTextBlock contextRef="c0" id="ixv-2965">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;The Company has incurred recurring losses
from operations and had an accumulated deficit of approximately $11.7 million as of June 30, 2026. Since inception, the Company has financed
its operations primarily through the issuance of equity securities and convertible notes. As of June 30, 2026, the Company had cash and
cash equivalents of $193 thousand.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During August 2026, the Company completed its
initial public offering (the &#x201c;IPO&#x201d;). Including proceeds from the exercise of the underwriter&#x2019;s over-allotment option,
the Company received aggregate net proceeds of approximately $84.9 million from the IPO after deducting underwriting discounts and commissions
and offering expenses payable by the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;Management considered the successful completion
of the IPO and the exercise of the overallotment option in its evaluation of the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;Based on the Company&#x2019;s current operating
plan and available cash resources, including the net proceeds received from the IPO and related overallotment option exercise, management
believes the Company&#x2019;s cash and cash equivalents will be sufficient to fund operations and meet its obligations for at least 12
months from the date these financial statements are issued. Accordingly, management has concluded that substantial doubt regarding the
Company&#x2019;s ability to continue as a going concern does not exist.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;The accompanying financial statements have
been prepared on a going concern basis.&lt;/p&gt;</vogx:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-5" id="ixv-11100" unitRef="usd">-11700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-11101" unitRef="usd">193000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c45" decimals="-5" id="ixv-11102" unitRef="usd">84900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <vogx:ReverseStockSplitPolicyTextBlock contextRef="c0" id="ixv-3003">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Reverse stock split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;On July 21, 2026 the Company&#x2019;s board
of directors approved a one-for-three reverse stock split, which was effected on July 28, 2026, of the Company&#x2019;s issued and outstanding
shares of common stock. Accordingly, all issued and outstanding share and per share amounts of common stock and stock option awards for
all periods presented in the accompanying financial statements and notes thereto have been adjusted retroactively, where applicable, to
reflect this reverse stock split. The par value of the common stock and preferred stock and the number of authorized shares were not changed
as a result of the reverse stock split.&lt;/p&gt;</vogx:ReverseStockSplitPolicyTextBlock>
    <vogx:InitialPublicOfferingPolicyTextBlock contextRef="c0" id="ixv-3011">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Initial public offering &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;In August 2026, the Company completed the
IPO, pursuant to which the Company issued and sold 7,187,500 shares of its common stock at a public offering price of $13.00 per share,
including 937,500 additional shares of its common stock pursuant to the exercise in full by the underwriter of its option to purchase
shares of common stock from the Company at the IPO price. As a result, the Company received net proceeds from the IPO of approximately
$84.9 million, after deducting underwriting discounts, commissions and offering expenses payable by the Company. Immediately prior to
the closing of the IPO, the Company&#x2019;s outstanding convertible preferred stock and convertible notes automatically converted into
1,951,246 shares of common stock and the Company&#x2019;s outstanding warrants were automatically cashlessly exercised for 453,183 shares
of common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;Following the closing of the IPO, no shares
of the Company&#x2019;s convertible preferred stock were authorized or outstanding. In connection with the completion of the IPO, on August
13, 2026, the Company&#x2019;s amended and restated certificate of incorporation, as amended, was amended and restated to (i) authorize
500 million shares of common stock, par value $0.0001 per share and (ii) authorize 10 million shares of undesignated preferred stock,
par value $0.0001 per share, that may be issued from time to time by the Company&#x2019;s board of directors from time to time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;The Company&#x2019;s unaudited condensed financial
statements as of and for the period ended June 30, 2026, including share and per share amounts, do not give effect to the IPO and related
actions as the IPO closed subsequent to June 30, 2026.&lt;/p&gt;</vogx:InitialPublicOfferingPolicyTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c45"
      decimals="0"
      id="ixv-11103"
      unitRef="shares">7187500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c46"
      decimals="2"
      id="ixv-11104"
      unitRef="usdPershares">13</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c47"
      decimals="0"
      id="ixv-11105"
      unitRef="shares">937500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c45" decimals="-5" id="ixv-11106" unitRef="usd">84900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="c45"
      decimals="0"
      id="ixv-11107"
      unitRef="shares">1951246</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c45"
      decimals="0"
      id="ixv-11108"
      unitRef="shares">453183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c48"
      decimals="-6"
      id="ixv-11109"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c48"
      decimals="4"
      id="ixv-11110"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <vogx:UndesignatedPreferredStockSharesAuthorized
      contextRef="c48"
      decimals="-6"
      id="ixv-11111"
      unitRef="shares">10000000</vogx:UndesignatedPreferredStockSharesAuthorized>
    <vogx:UndesignatedPreferredStockParValue
      contextRef="c48"
      decimals="4"
      id="ixv-11112"
      unitRef="usdPershares">0.0001</vogx:UndesignatedPreferredStockParValue>
    <vogx:ReclassificationsPolicyTextBlock contextRef="c0" id="ixv-3025">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Certain amounts reported previously have been reclassified to conform
to the current period presentation with no effect on total stockholders&#x2019; deficit or net loss as previously reported.&lt;/p&gt;</vogx:ReclassificationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-3033">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Segment information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company operates as a &lt;span style="-sec-ix-hidden: hidden-fact-0"&gt;single&lt;/span&gt; reportable segment engaged in the
discovery and development of treatments for serious metabolic and gastrointestinal diseases. The Company has not generated revenues since
inception. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is its Chief Executive Officer. The CODM reviews the
Company&#x2019;s performance on an aggregate basis; thus the segment&#x2019;s loss is the Company&#x2019;s net loss, as reported on accompanying
statements of operations, and the segment&#x2019;s assets are the Company&#x2019;s total assets, as reported on the accompanying balance
sheets. Significant expenses provided to the CODM include research and development and general and administrative expenses, as reported
on the accompanying statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The CODM uses the information primarily to evaluate the Company&#x2019;s
performance and allocate resources. The CODM&#x2019;s evaluation includes reviewing key financial metrics such as budget versus actual
expenditures and assessing overall cash flow and liquidity to ensure the continuity of operations. This approach allows the CODM to monitor
the Company&#x2019;s performance and make strategic adjustments as needed to support its operational and financial goals.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company&#x2019;s operations and all long-lived assets are located
in the United States.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table presents the measure of segment loss and the significant
expense categories regularly provided to the CODM for the three and six months ended June 30, 2026 and June 30, 2025:&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="font-size: 9pt; vertical-align: bottom"&gt;
    &lt;td style="font-size: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three&lt;br/&gt; Months Ended &lt;br/&gt; June 30,&lt;br/&gt; 2026&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three&lt;br/&gt; Months Ended &lt;br/&gt; June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six &lt;br/&gt; Months Ended &lt;br/&gt; June 30,&lt;br/&gt; 2026&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six&lt;br/&gt; Months Ended &lt;br/&gt; June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Significant segment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 9pt"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;156,786&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;136,392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;394,695&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;305,703&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,598&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;174,268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;423,841&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;377,155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Other segment expense (income)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;29,046&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(15,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;41,346&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(31,442&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Segment net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(384,430&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(294,797&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(859,882&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(651,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0" id="ixv-3064">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table presents the measure of segment loss and the significant
expense categories regularly provided to the CODM for the three and six months ended June 30, 2026 and June 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="font-size: 9pt; vertical-align: bottom"&gt;
    &lt;td style="font-size: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three&lt;br/&gt; Months Ended &lt;br/&gt; June 30,&lt;br/&gt; 2026&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three&lt;br/&gt; Months Ended &lt;br/&gt; June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six &lt;br/&gt; Months Ended &lt;br/&gt; June 30,&lt;br/&gt; 2026&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six&lt;br/&gt; Months Ended &lt;br/&gt; June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Significant segment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 9pt"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;156,786&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;136,392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;394,695&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;305,703&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,598&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;174,268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;423,841&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;377,155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Other segment expense (income)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;29,046&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(15,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;41,346&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(31,442&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Segment net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(384,430&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(294,797&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(859,882&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(651,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" id="ixv-11113" unitRef="usd">156786</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" id="ixv-11114" unitRef="usd">136392</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-11115" unitRef="usd">394695</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="0" id="ixv-11116" unitRef="usd">305703</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="0" id="ixv-11117" unitRef="usd">198598</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" id="ixv-11118" unitRef="usd">174268</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-11119" unitRef="usd">423841</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="0" id="ixv-11120" unitRef="usd">377155</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c4" decimals="0" id="ixv-11121" unitRef="usd">29046</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c5" decimals="0" id="ixv-11122" unitRef="usd">-15863</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-11123" unitRef="usd">41346</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c6" decimals="0" id="ixv-11124" unitRef="usd">-31442</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" id="ixv-11125" unitRef="usd">-384430</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-11126" unitRef="usd">-294797</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-11127" unitRef="usd">-859882</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-11128" unitRef="usd">-651416</us-gaap:NetIncomeLoss>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c0" id="ixv-3187">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Deferred offering costs &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;The Company capitalizes as deferred offering
costs all direct and incremental legal, accounting, underwriting and other third-party fees incurred in connection with the IPO. Upon
the consummation of the IPO, such costs are offset against the gross proceeds received from the IPO. As of June 30, 2026 and December
31, 2025, the Company had deferred offering costs of $1,204,631 and $63,363, respectively, of which $1,056,394 was included in accounts
payable as of June 30, 2026.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts contextRef="c2" decimals="0" id="ixv-11129" unitRef="usd">1204631</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts contextRef="c3" decimals="0" id="ixv-11130" unitRef="usd">63363</us-gaap:DeferredOfferingCosts>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c2" decimals="0" id="ixv-11131" unitRef="usd">1056394</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-3195">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Fair value measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;ASC Topic 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, establishes a fair value
hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Level 1&lt;/i&gt; &#x2013; This level consists of quoted prices (unadjusted)
for identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Level 2&lt;/i&gt; - This level consists of inputs that include quoted
prices for similar assets and liabilities in active markets and inputs that are observable for the asset or liability, either directly
or indirectly, for substantially the full term of the financial instrument. Fair values for these instruments are estimated using pricing
models, quoted prices of securities with similar characteristics, or discounted cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Level 3&lt;/i&gt; - This level consists of inputs that are unobservable
inputs for the assets or liability, which are typically based on an entity&#x2019;s own assumptions, as there is little, if any, related
market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair
value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level
input that is significant to the fair value measurement in its entirety.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The carrying amounts of the Company&#x2019;s financial instruments,
which include cash and cash equivalents, prepaids and other current assets, accounts payable, deferred offering costs and accrued expenses
approximate their fair values at June 30, 2026 and December 31, 2025 due to their short-term nature for these Level 1 instruments and
management&#x2019;s conclusion that their carrying amounts approximate the amount for which the assets could be sold or the liabilities
could be settled.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of June 30, 2026, and December 31, 2025, the Company&#x2019;s liabilities
measured at fair value on a recurring basis included the warrant liability and convertible promissory notes payable, related party which
were measured using Level 3 inputs. There were no transfers between fair value hierarchy levels during the three and six months ended
June 30, 2026, and the year ended December 31, 2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table summarizes the change in fair value, as determined
by the Level 3 inputs, for the warrant liability, and convertible promissory notes payable, related party using unobservable Level 3 inputs
as of June 30, 2026 and December 31, 2025:&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Convertible&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Warrant&lt;br/&gt;
    Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Promissory
    Notes&lt;br/&gt;
    Payable,&lt;br/&gt;
    Related&lt;br/&gt;
    Party&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;65,107&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Fair value balance as of December 8, 2025, issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;810,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(53,784&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Balance as of December 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;816,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9,908&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;51,400&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of June 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,415&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;867,700&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table presents quantitative information about the
inputs and valuation methodologies used for the Company&#x2019;s fair value measurements classified as Level 3 as of June 30, 2026 and
December 31, 2025:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;As
    of June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Valuation
    Methodology&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Significant
    Input&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    (range, if applicable)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 35%; text-align: left"&gt;Convertible promissory notes payable, related
    party&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Probability Weighted Average Return Method (PWERM)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 21%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit spread
    &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;9.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.9-4.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Probability &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0-100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25-0.69 years&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Black-Scholes Option Pricing Model&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.01&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annualized volatility&#160;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Expected term&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.5 years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;As
    of December&#160;31,&#160;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Valuation
    Methodology&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Significant
    Input&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Weighted&lt;br/&gt;

    Average &lt;br/&gt;
(range, if applicable)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 35%; text-align: left"&gt;Convertible promissory notes payable, related
    party&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Probability Weighted Average Return Method (PWERM)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 21%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit spread
    &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;8.9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.5-3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Probability &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0-100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.5 &#x2013; 1.18 years&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Black-Scholes Option Pricing Model&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.73&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annualized volatility&#160;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Expected term&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.97 years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: justify"&gt;Represents significant unobservable input&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="c0" id="ixv-3238">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table summarizes the change in fair value, as determined
by the Level 3 inputs, for the warrant liability, and convertible promissory notes payable, related party using unobservable Level 3 inputs
as of June 30, 2026 and December 31, 2025:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Convertible&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Warrant&lt;br/&gt;
    Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Promissory
    Notes&lt;br/&gt;
    Payable,&lt;br/&gt;
    Related&lt;br/&gt;
    Party&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;65,107&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Fair value balance as of December 8, 2025, issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;810,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(53,784&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Balance as of December 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;816,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9,908&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;51,400&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of June 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,415&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;867,700&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c49" decimals="0" id="ixv-11132" unitRef="usd">65107</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c50" decimals="0" id="ixv-11133" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c51" decimals="0" id="ixv-11134" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c52" decimals="0" id="ixv-11135" unitRef="usd">810500</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c53" decimals="0" id="ixv-11136" unitRef="usd">53784</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c54" decimals="0" id="ixv-11137" unitRef="usd">-5800</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c51" decimals="0" id="ixv-11138" unitRef="usd">11323</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c52" decimals="0" id="ixv-11139" unitRef="usd">816300</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c55" decimals="0" id="ixv-11140" unitRef="usd">9908</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c56" decimals="0" id="ixv-11141" unitRef="usd">-51400</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c57" decimals="0" id="ixv-11142" unitRef="usd">1415</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c58" decimals="0" id="ixv-11143" unitRef="usd">867700</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c0" id="ixv-3345">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table presents quantitative information about the
inputs and valuation methodologies used for the Company&#x2019;s fair value measurements classified as Level 3 as of June 30, 2026 and
December 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;As
    of June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Valuation
    Methodology&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Significant
    Input&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    (range, if applicable)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 35%; text-align: left"&gt;Convertible promissory notes payable, related
    party&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Probability Weighted Average Return Method (PWERM)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 21%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit spread
    &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;9.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.9-4.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Probability &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0-100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25-0.69 years&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Black-Scholes Option Pricing Model&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.01&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annualized volatility&#160;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Expected term&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.5 years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;As
    of December&#160;31,&#160;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Valuation
    Methodology&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Significant
    Input&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Weighted&lt;br/&gt;

    Average &lt;br/&gt;
(range, if applicable)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 35%; text-align: left"&gt;Convertible promissory notes payable, related
    party&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Probability Weighted Average Return Method (PWERM)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 21%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit spread
    &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;8.9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.5-3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Probability &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0-100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.5 &#x2013; 1.18 years&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Black-Scholes Option Pricing Model&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.73&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annualized volatility&#160;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Expected term&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.97 years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c59" decimals="1" id="ixv-11144" unitRef="pure">9.7</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c60" decimals="1" id="ixv-11145" unitRef="pure">3.9</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c61" decimals="1" id="ixv-11146" unitRef="pure">4</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c62" decimals="0" id="ixv-11147" unitRef="pure">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c63" decimals="0" id="ixv-11148" unitRef="pure">100</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c64" decimals="2" id="ixv-11149" unitRef="pure">0.25</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c65" decimals="2" id="ixv-11150" unitRef="pure">0.69</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c66" decimals="2" id="ixv-11151" unitRef="pure">4.01</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c67" decimals="2" id="ixv-11152" unitRef="pure">85</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c68" decimals="2" id="ixv-11153" unitRef="pure">1.14</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c69" decimals="2" id="ixv-11154" unitRef="pure">5.7</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c70" decimals="1" id="ixv-11155" unitRef="pure">0.5</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c71" decimals="1" id="ixv-11156" unitRef="pure">8.9</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c72" decimals="1" id="ixv-11157" unitRef="pure">3.5</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c73" decimals="1" id="ixv-11158" unitRef="pure">3.6</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c74" decimals="0" id="ixv-11159" unitRef="pure">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c75" decimals="0" id="ixv-11160" unitRef="pure">100</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c76" decimals="1" id="ixv-11161" unitRef="pure">0.5</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c77" decimals="2" id="ixv-11162" unitRef="pure">1.18</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c78" decimals="2" id="ixv-11163" unitRef="pure">3.73</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c79" decimals="2" id="ixv-11164" unitRef="pure">85</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c80" decimals="2" id="ixv-11165" unitRef="pure">1.14</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c81" decimals="2" id="ixv-11166" unitRef="pure">5.7</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="c82" decimals="2" id="ixv-11167" unitRef="pure">0.97</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-3665">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Recently issued accounting pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;From time to time, new accounting pronouncements
are issued by the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) or other standard-setting bodies and adopted by the Company
as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that
are not yet effective will not have a material impact on the accompanying financial statements and disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;In December 2025, the FASB issued ASU 2025-11
- Interim Reporting (Topic 270): Narrow-Scope Improvements (&#x201c;ASU 2025-11&#x201d;). ASU 2025-11 is intended to clarify and improve
certain aspects of interim financial reporting, including the requirements for interim disclosures and the application of recognition
and measurement guidance in interim periods. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning
after December 15, 2027. The Company is currently evaluating the potential impact of the guidance and potential additional disclosures
required.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;On November 2024, the FASB issued ASU 2024-03
- Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement
Expenses. This new standard requires more detailed disclosures about the types of expenses in commonly presented expense captions such
as cost of sales, selling, general and administrative expenses and research and development expenses. This includes separate footnote
disclosure for expenses such as purchases of inventory, employee compensation, depreciation, and intangible asset amortization. Public
business entities are required to apply the guidance prospectively and may apply it retrospectively. The ASU&#x2019;s amendments are effective
for public business entities for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December
15, 2027. The Company is currently evaluating the effect of adopting this ASU.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-3681">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0%"&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of June 30, 2026 and December 31, 2025, the Company had accrued
expenses of $1,095,543 and $709,818, respectively. At June 30, 2026, accrued expenses consist primarily of $719,043 in compensation payable
to the Company&#x2019;s officers, $286,500 for bonuses and $90,000 in fees to members of its board of directors. At December 31, 2025,
accrued expenses consist primarily of $363,318 in compensation payable to the Company&#x2019;s officers, $286,500 for bonuses and $60,000
in fees to members of its board of directors.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-11168" unitRef="usd">1095543</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-11169" unitRef="usd">709818</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount contextRef="c2" decimals="0" id="ixv-11170" unitRef="usd">719043</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent contextRef="c2" decimals="0" id="ixv-11171" unitRef="usd">286500</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:NoninterestExpenseDirectorsFees contextRef="c0" decimals="0" id="ixv-11172" unitRef="usd">90000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount contextRef="c3" decimals="0" id="ixv-11173" unitRef="usd">363318</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent contextRef="c3" decimals="0" id="ixv-11174" unitRef="usd">286500</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:NoninterestExpenseDirectorsFees contextRef="c83" decimals="0" id="ixv-11175" unitRef="usd">60000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-3696">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0%"&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&lt;b&gt;Convertible Promissory Notes Payable, Related Party&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On December 8, 2025, the Company issued unsecured convertible promissory
notes to the Company&#x2019;s Chief Financial Officer (also a director), an entity owned by another director, and an entity owned by a
close relative of the Company&#x2019;s Chief Scientific Officer (also a director), all related parties (&#x201c;Notes&#x201d;), for an aggregate
principal amount of $750,000 with a stated interest rate of 12% per annum to pursue fundraising and general corporate purposes. In the
event of an initial public offering the principal amount of the Notes would automatically convert into shares of the Company&#x2019;s common
stock at a conversion price equal to 90% of the per share price of the Company&#x2019;s common stock sold in the initial public offering.
In the event of a Qualified Financing (as defined in the Notes) the principal amount of the Notes would automatically convert into Conversion
Shares (as defined in the Notes) at a conversion price equal to 90% of the per share price of the Conversion Shares issued in such Qualified
Financing. In the event of an Optional Financing (as defined in the Notes), subject to the consent of the holders, the principal amount
of the Notes would automatically convert into the securities issued in such transaction at 90% of the per-share price (or equivalent)
paid by investors in such transaction or, if no such price is readily determinable, at a price per share equal to 90% of the fair market
value of the Company&#x2019;s common stock as reasonably determined in good faith by the Company&#x2019;s board of directors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Notes had a maturity of 15 months and if the Company has not closed
an equity financing by the date that is 10 months after the issuance date of the Notes, the rate would increase to 18% per annum. Interest
under the Notes was payable in cash. &lt;span&gt;The Notes are presented as a current liability on the balance
sheet. This classification is based on management&#x2019;s judgment that the Notes were expected to be converted within one year from the
balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Because of the variable nature of the embedded conversion features,
the Notes have been accounted for in accordance with ASC Topic 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC 815&#x201d;). The Notes
were valued using a probability-weighted expected return method (PWERM), which estimates fair value by modeling the expected payoffs under
each scenario, discounting each scenario&#x2019;s payoff to the Valuation Date, and then probability-weighting the present values. The
analysis considered four primary scenarios: (i) automatic conversion upon an initial public offering, (ii) automatic conversion upon a
Qualified Financing, (iii) an optional conversion upon other financing and (iv) repayment of principal and accrued interest at Maturity
in the absence of an initial public offering or financing events, with scenario probabilities based on discussions with management regarding
anticipated financing plans and timing. Because the expected payoff under each scenario is fixed at the time of settlement and does not
vary with future equity value beyond the conversion event, the instrument exhibits debt-like characteristics; accordingly, expected payoffs
were discounted using a rate reflecting the obligor&#x2019;s credit risk, calculated as the sum of a term-matched risk-free rate and an
appropriate credit spread. At June 30, 2026, there was a difference in the aggregate fair value and the aggregate unpaid principal balance
of the convertible promissory note payable, related party of $117,700.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Immediately prior to the closing of the IPO, the
convertible notes converted into 64,102 shares of the Company&#x2019;s common stock at a price per share equal to 90% of the public offering
price in the IPO.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c84" decimals="0" id="ixv-11176" unitRef="usd">750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c84" decimals="2" id="ixv-11177" unitRef="pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c85" decimals="2" id="ixv-11178" unitRef="pure">0.90</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c85" decimals="2" id="ixv-11179" unitRef="pure">0.90</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtInstrumentTerm contextRef="c85" id="ixv-11180">P15M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="c85" decimals="2" id="ixv-11181" unitRef="pure">0.18</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:ConvertibleNotesPayable contextRef="c86" decimals="0" id="ixv-11182" unitRef="usd">117700</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="c87"
      decimals="0"
      id="ixv-11183"
      unitRef="shares">64102</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <vogx:PercentageOfPublicOfferingPrice contextRef="c87" decimals="2" id="ixv-11184" unitRef="pure">0.90</vogx:PercentageOfPublicOfferingPrice>
    <vogx:WarrantsDisclosureTextBlock contextRef="c0" id="ixv-3733">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 24px; text-align: left"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company accounts for warrants as either equity-classified or liability-classified
instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in ASC Topic 480,&#160;Distinguishing
Liabilities from Equity&#160;(&#x201c;ASC 480&#x201d;), and ASC 815. The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, whether the warrants meet the definition of a liability pursuant to ASC 480, and whether the warrants
meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s
own common stock and whether the warrants may require&#x2014;outside the Company&#x2019;s control&#x2014;settlement through transferring
assets, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted
at the time of warrant issuance and at the time of any modification while the warrants are outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Warrants classified as equity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During December 2021 and January 2022, 188,715 pre-funded common
stock warrants were issued to the Company&#x2019;s placement agent in connection with the Company&#x2019;s Series A Convertible Preferred
Stock financing and accounted for as equity as part of the placement agent&#x2019;s services. The warrants had a term of seven and one-half
years from the original issuance date and an exercise price of $0.03 per share. As of June 30, 2026 and December 31, 2025 there were 188,715
warrants outstanding with a weighted average exercise price of $0.03, a weighted average remaining contractual term of 3 and 3.5 years,
respectively and a weighted average grant date fair value of $0.90. There was no change in the number of warrants classified as equity
during the quarter ended June 30, 2026. Immediately prior to the closing of the IPO, these warrants were cashlessly exercised for an aggregate
of 188,279 shares of the Company&#x2019;s common stock.&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Warrants classified as liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company issued 471,805 warrants to purchase common stock with
an exercise price of $5.70 in connection with its Series A Convertible Preferred Stock offering in December 2021 and January 2022. The
warrants were issued to purchasers of the Company&#x2019;s Series A Convertible Preferred Stock and had a five year term from the original
issuance date. The warrants have been recorded as liability-classified instruments at estimated fair value. The Company adjusts the liability
for changes in fair value until the earlier of the exercise or expiration of the warrants. Any change in fair value of the warrant liability
is recognized in the statement of operations under the change in fair value of warrant liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The estimated fair value of the warrants on the date of issuance was
determined using Level 3 inputs on December 21, 2021 and January 28, 2022 the dates of issuance. Inherent in a Black-Scholes-Merton (&#x201c;BSM&#x201d;)
model are assumptions related to expected share-price volatility, expected term, and risk-free interest rate. The Company estimates the
volatility of its common stock based on management&#x2019;s understanding of the volatility associated with instruments of other similar
entities. The risk-free interest rate is based on the U.S. Treasury Constant Maturity similar to the expected remaining life of the warrants.
The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The assumptions used in calculating
the estimated fair values at the end of the reporting period represent the Company&#x2019;s best estimate and include the annualized volatility
percentage.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;However, inherent uncertainties are involved. If factors or assumptions
change, the estimated fair values could be materially different.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of June 30, 2026 and December 31, 2025, there were 471,805
warrants outstanding with a weighted average exercise price of $5.70, a weighted average remaining contractual term of six months and
one year, respectively, and a weighted average grant date fair value of $0.33. There was no change in the number of warrants classified
as liability during the quarter ended June 30, 2026. Immediately prior to the closing of the IPO, these warrants were cashlessly exercised
for an aggregate of 264,904 shares of the Company&#x2019;s common stock.&lt;/p&gt;</vogx:WarrantsDisclosureTextBlock>
    <vogx:ClassOfWarrantOrRightIssued
      contextRef="c88"
      decimals="0"
      id="ixv-11185"
      unitRef="shares">188715</vogx:ClassOfWarrantOrRightIssued>
    <vogx:ClassOfWarrantOrRightIssued
      contextRef="c89"
      decimals="0"
      id="ixv-11186"
      unitRef="shares">188715</vogx:ClassOfWarrantOrRightIssued>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c89" id="ixv-11187">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c88" id="ixv-11188">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c88"
      decimals="2"
      id="ixv-11191"
      unitRef="usdPershares">0.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c89"
      decimals="2"
      id="ixv-11192"
      unitRef="usdPershares">0.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c90"
      decimals="0"
      id="ixv-11193"
      unitRef="shares">188715</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c91"
      decimals="0"
      id="ixv-11194"
      unitRef="shares">188715</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c90"
      decimals="2"
      id="ixv-11195"
      unitRef="usdPershares">0.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c91"
      decimals="2"
      id="ixv-11196"
      unitRef="usdPershares">0.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c90" id="ixv-11197">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c91" id="ixv-11198">P3Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c92"
      decimals="2"
      id="ixv-11199"
      unitRef="usdPershares">0.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c92"
      decimals="0"
      id="ixv-11200"
      unitRef="shares">188279</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vogx:WarrantsToPurchaseCommonStock
      contextRef="c93"
      decimals="0"
      id="ixv-11201"
      unitRef="shares">471805</vogx:WarrantsToPurchaseCommonStock>
    <vogx:WarrantsToPurchaseCommonStock
      contextRef="c94"
      decimals="0"
      id="ixv-11202"
      unitRef="shares">471805</vogx:WarrantsToPurchaseCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c95"
      decimals="2"
      id="ixv-11203"
      unitRef="usdPershares">5.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c96"
      decimals="2"
      id="ixv-11204"
      unitRef="usdPershares">5.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c97" id="ixv-11205">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c97"
      decimals="0"
      id="ixv-11206"
      unitRef="shares">471805</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c98"
      decimals="0"
      id="ixv-11207"
      unitRef="shares">471805</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c97"
      decimals="2"
      id="ixv-11208"
      unitRef="usdPershares">5.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c98"
      decimals="2"
      id="ixv-11209"
      unitRef="usdPershares">5.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c99" id="ixv-11210">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c100" id="ixv-11211">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c99"
      decimals="2"
      id="ixv-11212"
      unitRef="usdPershares">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c99"
      decimals="0"
      id="ixv-11213"
      unitRef="shares">264904</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-3782">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;6. Stockholders&#x2019; Deficit &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On December 15, 2021, in connection with the filing of the Company&#x2019;s
amended and restated certificate of incorporation, the Company increased the total number of authorized shares of all classes of stock
to 50,000,000 shares of common stock and 15,000,000 shares of preferred stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The holders of shares of Series A Convertible Preferred Stock had the
following rights and preferences:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Liquidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In the event of any liquidation, dissolution or winding up of the Company,
the holders of Series A Convertible Preferred Stock were entitled to be paid out of Company assets, available for distribution to its
stockholders, in preference to the holders of common stock. The holders of Series A Convertible Preferred Stock were to be paid an amount
per share equal to the greater of (i) the Series Original Issue Price of $1.90 per share plus any dividends declared but unpaid or (ii)
an amount per share as would have been payable had all shares of preferred stock been converted into common stock plus and dividends declared
but unpaid. If Company assets were not sufficient to pay the holders of Series A Convertible Preferred Stock in full, they will share
ratably in any distribution in proportion to the respective convertible amounts held by each holder of preferred stock. After the holders
of Series A Convertible Preferred Stock are paid in full, the holders of common stock are entitled on a ratable basis to all remaining
assets of the Company.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Mandatory conversion&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Each share of Series A Convertible Preferred Stock was mandatorily
convertible upon either (i) the closing of the sale of shares of common stock to the public at a price of at least $14.25 per share in
a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended,
or (ii) the date and time, or the occurrence of an event, specified by vote or written consent of the holders of a majority of the Series
A Convertible Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Optional conversion&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Each share of Series A Convertible Preferred Stock was convertible
at the option of the holder at any time into shares of common stock as determined by dividing the applicable Original Issue Price by the
applicable Conversion Price (initially the applicable Original Issue Price). The Conversion Price was subject to adjustment for dilutive
issuances.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Voting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The holders of Series A Convertible Preferred Stock were entitled to
vote equal to the number of whole shares of common stock into which the shares of preferred stock are convertible as of the record date
for determining stockholders entitled to vote on such matter. The holders of Series A Convertible Preferred Stock and common stock generally
voted together as one class.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c101"
      decimals="0"
      id="ixv-11214"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c101"
      decimals="0"
      id="ixv-11215"
      unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <vogx:DescriptionOfSeriesAConvertiblePreferredStock contextRef="c0" id="ixv-11216">The holders of Series A Convertible Preferred Stock were to be paid an amount
per share equal to the greater of (i) the Series Original Issue Price of $1.90 per share plus any dividends declared but unpaid or (ii)
an amount per share as would have been payable had all shares of preferred stock been converted into common stock plus and dividends declared
but unpaid.</vogx:DescriptionOfSeriesAConvertiblePreferredStock>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c102"
      decimals="2"
      id="ixv-11217"
      unitRef="usdPershares">14.25</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-3839">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 24px; text-align: left"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Net Loss Per Common Share&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company calculates net loss per common share in accordance with
ASC Topic 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the use of the two-class method because the Series A Convertible Preferred Stock
was entitled to participate in dividends. However, the Company has generated a net loss for each of the two periods presented. Because
the Series A Convertible Preferred Stock is not obligated to share in the Company&#x2019;s losses, the two-class method does not apply
in the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic and diluted net loss per common share was determined by dividing
net loss applicable to common stockholders by the weighted average number of common shares outstanding including 188,715 pre-funded warrants
issued to the Company&#x2019;s placement agent in connection with the issuance of the Company&#x2019;s Series A Convertible Preferred Stock.
As the Company&#x2019;s pre-funded warrants were issuable for little to no consideration and did not contain any conditions that must be
satisfied for the holder to receive the shares, the pre-funded warrants were included in the computation of basic and diluted net loss
per share. Basic and diluted net loss per share attributable to common stockholders were the same in the periods presented because the
inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;For the three and six months ended June 30, 2026, and 2025, all of
the Company&#x2019;s Series A Convertible Preferred Stock, common stock options, and warrants, with the exception of the pre-funded warrants
described above, issued to the Series A shareholders were anti-dilutive and therefore have been excluded from the diluted net loss per
share calculations.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table reconciles net loss and the securities used to
calculate weighted average shares outstanding:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="font-size: 9pt; vertical-align: bottom"&gt;
    &lt;td style="font-size: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 9pt; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 9pt; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-size: 9pt; vertical-align: bottom"&gt;
    &lt;td style="font-size: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; text-align: center; border-bottom: Black 1pt solid"&gt;2026&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; text-align: center; border-bottom: Black 1pt solid"&gt;2025&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; text-align: center; border-bottom: Black 1pt solid"&gt;2026&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; text-align: center; border-bottom: Black 1pt solid"&gt;2025&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(384,430&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(294,797&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(859,882&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(651,416&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,263,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,263,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,263,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,263,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrants - classified as equity&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;188,715&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;188,715&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;188,715&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;188,715&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Total weighted average shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,451,873&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,451,873&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,451,873&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,451,873&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss per common share - basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.07&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.05&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following potentially dilutive securities were excluded from the
calculation of net loss per share due to their anti-dilutive effect:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font: 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font: 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Six
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,887,144&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,887,144&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,887,144&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,887,144&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Stock options outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;561,657&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;446,659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;561,657&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;446,659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrants - classified as a liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;471,805&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;471,805&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;471,805&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;471,805&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,920,606&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,805,608&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,920,606&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,805,608&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <vogx:PrefundedWarrantsIssued
      contextRef="c0"
      decimals="0"
      id="ixv-11218"
      unitRef="shares">188715</vogx:PrefundedWarrantsIssued>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-3857">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="font-size: 9pt; vertical-align: bottom"&gt;
    &lt;td style="font-size: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 9pt; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 9pt; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-size: 9pt; vertical-align: bottom"&gt;
    &lt;td style="font-size: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; text-align: center; border-bottom: Black 1pt solid"&gt;2026&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; text-align: center; border-bottom: Black 1pt solid"&gt;2025&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; text-align: center; border-bottom: Black 1pt solid"&gt;2026&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 9pt; text-align: center; border-bottom: Black 1pt solid"&gt;2025&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(384,430&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(294,797&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(859,882&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(651,416&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,263,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,263,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,263,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,263,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrants - classified as equity&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;188,715&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;188,715&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;188,715&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;188,715&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Total weighted average shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,451,873&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,451,873&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,451,873&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,451,873&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss per common share - basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.07&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.05&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" id="ixv-11219" unitRef="usd">-384430</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-11220" unitRef="usd">-294797</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-11221" unitRef="usd">-859882</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-11222" unitRef="usd">-651416</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-11223"
      unitRef="shares">5263158</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c26"
      decimals="INF"
      id="ixv-11224"
      unitRef="shares">5263158</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-11225"
      unitRef="shares">5263158</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c26"
      decimals="INF"
      id="ixv-11226"
      unitRef="shares">5263158</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-11227"
      unitRef="shares">188715</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c26"
      decimals="INF"
      id="ixv-11228"
      unitRef="shares">188715</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-11229"
      unitRef="shares">188715</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c26"
      decimals="INF"
      id="ixv-11230"
      unitRef="shares">188715</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c4"
      decimals="INF"
      id="ixv-11231"
      unitRef="shares">5451873</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="INF"
      id="ixv-11232"
      unitRef="shares">5451873</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-11233"
      unitRef="shares">5451873</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="INF"
      id="ixv-11234"
      unitRef="shares">5451873</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="ixv-11235"
      unitRef="usdPershares">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c4"
      decimals="2"
      id="ixv-11236"
      unitRef="usdPershares">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="ixv-11237"
      unitRef="usdPershares">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c5"
      decimals="2"
      id="ixv-11238"
      unitRef="usdPershares">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-11239"
      unitRef="usdPershares">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-11240"
      unitRef="usdPershares">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-11241"
      unitRef="usdPershares">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-11242"
      unitRef="usdPershares">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-3992">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font: 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font: 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;Six
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,887,144&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,887,144&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,887,144&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,887,144&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Stock options outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;561,657&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;446,659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;561,657&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;446,659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrants - classified as a liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;471,805&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;471,805&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;471,805&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;471,805&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,920,606&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,805,608&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,920,606&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,805,608&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c103"
      decimals="INF"
      id="ixv-11243"
      unitRef="shares">1887144</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c104"
      decimals="INF"
      id="ixv-11244"
      unitRef="shares">1887144</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c105"
      decimals="INF"
      id="ixv-11245"
      unitRef="shares">1887144</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c106"
      decimals="INF"
      id="ixv-11246"
      unitRef="shares">1887144</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c107"
      decimals="INF"
      id="ixv-11247"
      unitRef="shares">561657</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c108"
      decimals="INF"
      id="ixv-11248"
      unitRef="shares">446659</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c109"
      decimals="INF"
      id="ixv-11249"
      unitRef="shares">561657</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c110"
      decimals="INF"
      id="ixv-11250"
      unitRef="shares">446659</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c111"
      decimals="INF"
      id="ixv-11251"
      unitRef="shares">471805</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c112"
      decimals="INF"
      id="ixv-11252"
      unitRef="shares">471805</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c113"
      decimals="INF"
      id="ixv-11253"
      unitRef="shares">471805</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c114"
      decimals="INF"
      id="ixv-11254"
      unitRef="shares">471805</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c4"
      decimals="INF"
      id="ixv-11255"
      unitRef="shares">2920606</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c5"
      decimals="INF"
      id="ixv-11256"
      unitRef="shares">2805608</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="INF"
      id="ixv-11257"
      unitRef="shares">2920606</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c6"
      decimals="INF"
      id="ixv-11258"
      unitRef="shares">2805608</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c4" id="ixv-11259">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c4" id="ixv-11260">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c4" id="ixv-11261">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c4" id="ixv-11262">false</ecd:Rule10b51ArrAdoptedFlag>
    <us-gaap:NumberOfReportableSegments
      contextRef="c0"
      decimals="0"
      id="hidden-fact-0"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-11266">0001903784</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-11267">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-11268">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-11269">--12-31</dei:CurrentFiscalYearEndDate>
</xbrl>
